Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis

NCT00235872 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00235872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00235872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2004
Completion date
Not reported
Enrollment
309 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis